NYSE:IQV - Iqvia Stock Price, Forecast & News

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) posted its quarterly earnings data on Wednesday, February, 12th. The medical research company reported $1.74 EPS for the quarter, beating analysts' consensus estimates of $1.72 by $0.02. The medical research company earned $2.90 billion during the quarter, compared to analyst estimates of $2.85 billion. Iqvia had a net margin of 1.72% and a return on equity of 17.65%. The business's quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.50 earnings per share. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Iqvia.

Iqvia issued an update on its FY20 earnings guidance on Wednesday, February, 12th. The company provided earnings per share (EPS) guidance of $7.15-7.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.22. The company issued revenue guidance of 11.775-12.000 billion, compared to the consensus revenue estimate of $11.84 billion.

17 analysts have issued 12 month price objectives for Iqvia's stock. Their forecasts range from $136.38 to $200.00. On average, they anticipate Iqvia's stock price to reach $176.21 in the next year. This suggests a possible upside of 17.4% from the stock's current price. View Analyst Price Targets for Iqvia.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Media coverage about IQV stock has been trending very negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Iqvia earned a news impact score of -3.0 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Iqvia.

Iqvia saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,250,000 shares, a decline of 5.2% from the January 15th total of 3,430,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the short-interest ratio is currently 2.5 days. Approximately 1.8% of the shares of the stock are short sold. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), PRA Health Sciences (PRAH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY) and Anavex Life Sciences (AVXL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Paypal (PYPL), Allergan (AGN) and Accenture (ACN).

Iqvia's stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (4.02%), Jackson Square Partners LLC (2.68%), FMR LLC (2.16%), Janus Henderson Group PLC (2.13%), Alliancebernstein L.P. (2.02%) and Capital Research Global Investors (1.78%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Farallon Capital Management LLC, Renaissance Technologies LLC, Citigroup Inc., AMF Pensionsforsakring AB, First Trust Advisors LP, Jackson Square Partners LLC and Castleark Management LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko and Michael R Mcdonnell. View Insider Buying and Selling for Iqvia.

IQV stock was acquired by a variety of institutional investors in the last quarter, including AustralianSuper Pty Ltd, Goldman Sachs Group Inc., Point72 Asset Management L.P., Loomis Sayles & Co. L P, Bessemer Group Inc., Assenagon Asset Management S.A., Alliancebernstein L.P. and State Street Corp. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $150.06.

Iqvia has a market capitalization of $28.86 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.View Additional Information About Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]